Compare SHMD & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHMD | HOWL |
|---|---|---|
| Founded | 1864 | 2017 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.2M | 64.5M |
| IPO Year | N/A | 2021 |
| Metric | SHMD | HOWL |
|---|---|---|
| Price | $5.86 | $0.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | 208.8K | ★ 851.9K |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $85,165,542.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.86 | $0.56 |
| 52 Week High | $6.70 | $2.38 |
| Indicator | SHMD | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 63.97 | 32.32 |
| Support Level | $4.70 | $0.61 |
| Resistance Level | $5.40 | $0.74 |
| Average True Range (ATR) | 0.64 | 0.09 |
| MACD | 0.07 | -0.03 |
| Stochastic Oscillator | 77.36 | 14.30 |
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.